healthcare-thumbnail.png

BRAF Mutated Non-Small Cell Lung Cancer (NSCLC) Market Research Report

Published: 2025 - January

Report Code: VMR-17726

Region: Global

Request Sample
Customization
Ask an Expert
Enquire Enquire Before Buying

BRAF Mutated Non-Small Cell Lung Cancer (NSCLC) Market Analysis

The BRAF Mutated Non-Small Cell Lung Cancer (NSCLC) Market is a specialized segment of the oncology therapeutics landscape targeting patients with genetic alterations in the BRAF gene, primarily the V600E mutation. This market encompasses targeted therapies, immunotherapy combinations, and innovative treatment strategies, addressing the unique challenges of managing this aggressive cancer subtype. It serves as a pivotal area for precision medicine, advancing outcomes through mutation-specific treatments.

Disruptive Impact and Opportunities:

The market has demonstrated disruptive potential by enabling tailored interventions with enhanced efficacy and minimized side effects. Emerging opportunities stem from next-generation therapeutics that combine ease of administration, safety profiles, and scalability, creating a significant market size. The integration of biomarker-driven approaches into clinical workflows has unlocked new avenues for therapeutic development, offering transformative solutions for patients.

BRAF Mutated Non-Small Cell Lung Cancer (NSCLC) Market Segmentation: Emerging Drugs

  • BRAFTOVI (encorafenib) + MEKTOVI (binimetinib)

  • ABM-1310

  • LXH254

  • Enfortumab Vedotin

BRAF Mutated Non-Small Cell Lung Cancer (NSCLC) Market Segmentation: Marketed Drugs

  • Dabrafenib

  • Vemurafenib

  • Trametinib

Key Companies

  • Array BioPharma (a Pfizer company)

  • ONO Pharmaceuticals

  • ABM Therapeutics

  • Novartis

  • Astellas Pharma

  • Seattle Genetics (a Seagen company)

  • Hoffmann-La Roche

  • Merck

  • AstraZeneca

BRAF Mutated Non-Small Cell Lung Cancer (NSCLC) Market Segmentation: By Type

  • BRAF Mutation Subtype

    • BRAF V600E Mutation

    • Non-V600E BRAF Mutations

  • Therapy Type

    • Targeted Therapy

      • BRAF Inhibitors

      • MEK Inhibitors

    • Immunotherapy

    • Chemotherapy

    • Combination Therapy

  • Line of Therapy

    • First-Line Therapy

    • Second-Line Therapy

    • Salvage Therapy

BRAF Mutated Non-Small Cell Lung Cancer (NSCLC) Market Segmentation: By Administration Type

  • Route of Administration

    • Oral

    • Intravenous (IV)

    • Combination Routes

  • Dosage Form

    • Tablets

    • Capsules

    • Injectable Solutions

  • Treatment Setting

    • Hospital-Based Treatment

    • Ambulatory and Outpatient Clinics

    • Home-Based Treatment

What’s in It for You?

  • Insights into innovative therapies and market dynamics.

  • Identification of growth opportunities through pipeline analysis.

  • Strategic guidance on partnerships and acquisitions.

  • Market forecasts supporting investment decisions.

  • Tailored recommendations for market penetration and expansion.

  • Detailed competitor analysis to enhance strategic planning.

  1. Braf Mutated Non Small Cell Lung Cancer Market - Executive Summary

    1. Introduction

    2. Objectives

    3. Key Findings

      1. Market Size 2025 & 2030: By Key Country (10MM)

      2. Global Market Size 2025 & 2030: By Key Segment

      3. Key Investments & Startup Analysis

    4. Research Methodology

  2. Understanding the Disease

    1. Disease Overview

    2. Classification

    3. Signs and Symptoms

    4. Risk Factors

    5. Causes

    6. Disease Biology & Digital Innovations

    7. Stages & Staging System

    8. Diagnostic Algorithm

    9. Current Treatment Practices & Algorithm

    10. Current Standard of Care and Treatment Gaps

    11. Patient Demographics and Treatment Pathways

  3. Guidelines

  4. Unmet Needs

  5. Epidemiology and Patient Population

    1. Epidemiology Key Findings

    2. Assumptions and Rationale: 10MM

    3. Epidemiology Scenario: 10MM

    4. U.S. Epidemiology Scenario

    5. EU-5 Epidemiology

      1. U.K. Epidemiology Scenario

      2. Germany Epidemiology Scenario

      3. France Epidemiology Scenario

      4. Italy Epidemiology Scenario

      5. Spain Epidemiology Scenario

    6. Japan Epidemiology Scenario

    7. China Epidemiology Scenario

    8. Australia Epidemiology Scenario

    9. India Epidemiology Scenario   

  6. Real-world Data & Real-world Evidence

  7. Drug Development Landscape

    1. Existing Key Drug Candidate Profiles/ Marketed Therapies

    2. Competitive Analysis and Differentiation

    3. Overview of Similar/Competing Drugs in Clinical Trials

    4. Future Trends and Emerging Drugs

  8. Regulatory Strategy and Potential Challenges

    1. Regulatory Pathways in Key Markets

    2. Anticipated Regulatory Hurdles and Mitigation Strategies

    3. Case Studies in Oncology Drug Regulation

    4. Impact of Potential Changes to Regulatory Framework

  9. Commercial Landscape

    1. Market Size & Growth Rates

    2. Key Approvals & Anticipated Loss of Exclusivity

    3. PESTLE & Porter’s Five Forces Analysis

    4. Market Shares, Positioning/Ranking

    5. Market Drivers

    6. Identification of Threats

    7. Digital Evolution in Commercialization

  10. Market Segmentation

  11. Pricing, Reimbursement, and Access

    1. Competitive Pricing Analysis

    2. Reimbursement Landscape and Challenges

    3. Strategies for Market Access and Equity

    4. Patient Spending/Expenditure Analysis

  12. Future Trends, Disruptions, and Opportunities

    1. Analysis of Emerging Trends

    2. Technological Impact

    3. Impact of Potential Market Disruptors

    4. Opportunities for Future Development and Expansion

    5. Considerations for Investment Opportunities

  13. Global Market Dynamics

    1. Regional Regulatory Disparities

    2. Cross-Border Partnership Strategies

    3. Global Supply Chain Dynamics

    4. Case Studies: Success and Failure in Global Markets

    5. Strategies for Global Expansion and Localization

  14. Company Profiles

 

 

Download Sample

↻

The field with (*) is required.

Choose License Type

$

2500

$

4250

$

5250

$

6900

Request Sample
Customization
Ask an Expert
Enquire Before Buying
customer-support

Analyst Support

Every order comes with Analyst Support.

report-custom

Customization

We offer customization to cater your needs to fullest.

verify

Verified Analysis

We value integrity, quality and authenticity the most.

© 2025 Virtue Market Research. All Rights Reserved.